ABSTRACT

Sphingolipids are lipids that have a sphingoid base and contain a group of aliphatic amino alcohols that contain sphingosine. Sphingolipids are essential in treatment of neurodegenerative, neuroinflammatory, and neuropsychiatric diseases. Sphingolipid imbalances can cause neurological and psychological problems. The emergence of diseases such as AD, PD, HD are linked to abnormal Sphingolipid metabolism. Sphingolipids play a role in neuronal demyelination, which can lead to diseases including Multiple Sclerosis. In clinical trials, prognostic biomarkers are used to investigate diseases and assess medication and treatment response. Prognostic biomarkers provide knowledge about the progression of the disease. In the case of ductal carcinoma of the breast, sphingosine kinase 1 (SPHK1) has prognostic significance. Sphingolipid metabolism is being studied as a possible prognostic biomarker for breast cancer. Sphingolipid changes have been identified in Melanoma, and Sphingomyelin synthase 1 (SMS1) has been linked to melanoma prognosis. Glycosphingolipids have also been identified as possible biomarkers for prostate cancer. Sphingolipidomics has advanced as a prognostic method for SLE an autoimmune disease. Sphingolipids and their metabolism are the focus of this study. S1P is also used to predict the outcome of CAP. In this present review, we give an overview of how sphingolipids plays a role as prognostic biomarker in neurological disorders and will provide knowledge about recent advances in investigational techniques. Keywords: Sphingolipids, Prognostic biomarkers, Methods of lipid investigation, neurological diseases, cancer
Publication date: 01/04/2022

https://ijbpas.com/pdf/2022/April/MS_IJBPAS_2022_6044.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.4.6044